Trial Profile
Safety and efficacy of Eltrombopag in the treatment of Immune thrombocytopenia porpura in a routine clinical practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2016
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Therapeutic Use
- 06 Sep 2016 New trial record